Mechanistic insights into Old English plants

Jasminum humile inhibits calcineurin. Credit: Geoffrey Kite

Often lacking in natural product drug discovery are ‘mechanistic insights’; that is, insights into the events at the molecular level that are behind any effects that plant compounds have on cells or organisms. With this in mind, Tom Prescott screened 250 Old English plants from the Queen’s Garden at Kew, to search for compounds that inhibit the human enzyme calcineurin. The results have been published in the Journal of Ethnopharmacology.

Calcineurin plays an important role in regulating human T-cell activation in the immune response, and inhibition of this process can be beneficial in certain auto-immune diseases.

Nepeta cataria and Teucrium chamaedrys showed initial promise but the compounds responsible (phenylpropanoid glycosides) were only strongly active against the basal, un-activated form of the enzyme.

Jasminum humile was found to be more promising as the ethanol extract inhibited both isolated human calcineurin enzyme and calcineurin-dependent gene expression in yeast cells. This demonstrated that plants do indeed produce compounds that directly inhibit .

More information: Prescott, T. A. K., et al. (2011). Direct inhibition of calcineurin by caffeoyl phenylethanoid glycosides from Teucrium chamaedrys and Nepeta cataria. Journal of Ethnopharmacology 137: 1306–1310.

Prescott, T. A. K., et al. (2012). Inhibition of human calcineurin and yeast calcineurin-dependent gene expression by Jasminum humile leaf and root extracts. Journal of Ethnopharmacology 140: 293-297.

add to favorites email to friend print save as pdf

Related Stories

Time to stop giving toxic drugs to kidney transplant patients?

Sep 22, 2011

Patients who receive kidney transplants must take lifelong medications that, while preventing organ rejection, can also compromise other aspects of health. Immunosuppresive drugs called calcineurin inhibitors protect transplanted ...

Recommended for you

Mirabegron for overactive bladder: Added benefit not proven

14 hours ago

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

User comments